Literature DB >> 6826811

The clinicopathologic spectrum of lymphomatoid papulosis: study of 31 cases.

N P Sanchez, M R Pittelkow, S A Muller, P M Banks, R K Winkelmann.   

Abstract

Herein we review the Mayo Clinic experience with thirty-one cases of lymphomatoid papulosis seen since 1965. All patients had chronic, recurrent, and self-healing erythematous papulonodular lesions, which often became pustular, ulcerated, and resolved with scarring. The clinical features often corresponded to those seen in Mucha-Habermann disease; however, the predominant histopathologic feature was an infiltrate composed primarily of atypical lymphoid cells suggestive of malignant lymphoma. In six patients, a lymphoproliferative disorder was eventually diagnosed. There were two cases of mycosis fungoides (stage I), one case of nodular sclerosing Hodgkin's disease, and three cases of malignant lymphoma--one diffuse mixed large and small cell type with features of T-immunoblastic type, one diffuse large cell type, and one follicular small cleaved cell type. The clinical course of the lymphomatoid papulosis was unaffected by chemotherapy for the lymphoproliferative disorder. Our data indicate that, with sufficient duration of follow-up, malignant lymphoma may develop in some patients with lymphomatoid papulosis.

Entities:  

Mesh:

Year:  1983        PMID: 6826811     DOI: 10.1016/s0190-9622(83)70011-3

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  9 in total

1.  Expression of a Hodgkin and Reed-Sternberg cell associated antigen (Ki-1) in cutaneous lymphoid infiltrates.

Authors:  E Ralfkiaer; J Bosq; K C Gatter; R Schwarting; J Gerdes; H Stein; D Y Mason
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

2.  Immunohistochemical distinction of lymphomatoid papulosis and pityriasis lichenoides et varioliformis acuta.

Authors:  F J Varga; E C Vonderheid; S M Olbricht; M E Kadin
Journal:  Am J Pathol       Date:  1990-04       Impact factor: 4.307

Review 3.  EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.

Authors:  Werner Kempf; Katrin Pfaltz; Maarten H Vermeer; Antonio Cozzio; Pablo L Ortiz-Romero; Martine Bagot; Elise Olsen; Youn H Kim; Reinhard Dummer; Nicola Pimpinelli; Sean Whittaker; Emmilia Hodak; Lorenzo Cerroni; Emilio Berti; Steve Horwitz; H Miles Prince; Joan Guitart; Teresa Estrach; José A Sanches; Madeleine Duvic; Annamari Ranki; Brigitte Dreno; Sonja Ostheeren-Michaelis; Robert Knobler; Gary Wood; Rein Willemze
Journal:  Blood       Date:  2011-08-12       Impact factor: 22.113

4.  Primary and secondary cutaneous Ki-1+ (CD30+) anaplastic large cell lymphomas. Morphologic, immunohistologic, and clinical-characteristics.

Authors:  P Kaudewitz; H Stein; F Dallenbach; F Eckert; K Bieber; G Burg; O Braun-Falco
Journal:  Am J Pathol       Date:  1989-08       Impact factor: 4.307

5.  Clonal composition of T cells in lymphomatoid papulosis.

Authors:  M E Kadin; E C Vonderheid; D Sako; L K Clayton; S Olbricht
Journal:  Am J Pathol       Date:  1987-01       Impact factor: 4.307

6.  Loss of receptors for transforming growth factor beta in human T-cell malignancies.

Authors:  M E Kadin; M W Cavaille-Coll; R Gertz; J Massagué; S Cheifetz; D George
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

Review 7.  Immunophenotypic and antigen receptor gene rearrangement analysis in T cell neoplasia.

Authors:  D M Knowles
Journal:  Am J Pathol       Date:  1989-04       Impact factor: 4.307

8.  Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis.

Authors:  Nadège Cordel; Benoît Tressières; Michel D'Incan; Laurent Machet; Florent Grange; Éric Estève; Sophie Dalac; Saskia Ingen-Housz-Oro; Martine Bagot; Marie Beylot-Barry; Pascal Joly
Journal:  Oncologist       Date:  2015-12-14

9.  Single-Fraction Radiotherapy for CD30(+) Lymphoproliferative Disorders.

Authors:  Michelle S Gentile; Maria Estela Martinez-Escala; Tarita O Thomas; Joan Guitart; Steven Rosen; Timothy Kuzel; Bharat B Mittal
Journal:  Biomed Res Int       Date:  2015-10-04       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.